Study of Shh medulloblastoma with U1 mutation
Part of Cancer clinical trials.
This study looks at people with a certain type of brain tumor called sonic hedgehog medulloblastoma that has come back or not responded to treatment. Researchers want to learn more about these tumors that have a specific genetic change (U1 mutation), which may help find better treatments in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 50 years old when first diagnosed.
- You must have a diagnosis of sonic hedgehog medulloblastoma (a type of brain tumor), confirmed by lab tests.
- Your tumor must have come back, not responded to treatment, or gotten worse after standard therapy like radiation and chemotherapy.
- You must have a sample of your tumor available for testing to check for the U1 mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This study looks at the long-term health of people who were treated for medulloblastoma with craniospinal radiation at St. Jude Children's Research Hospital. It aims to understand how they are doing years after treatment.
This trial compares two standard treatments for a type of brain tumor called SHH-activated medulloblastoma in children under 5. The goal is to see which treatment better protects thinking and learning skills over time.
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
This Phase 2 study looks at using a medication that blocks the “Sonic Hedgehog” pathway together with radiotherapy to reduce future problems from locally advanced basal cell carcinoma (BCC). It’s for people whose cancer responded completely to the first Sonic Hedgehog pathway inhibitor treatment and where doctors can confirm that response with a tissue test.
Hear when a new Medulloblastoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.